# Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer's disease patients.

- **DOI:** [10.1186/s13195-026-02092-7](https://doi.org/10.1186/s13195-026-02092-7)
- **Rating:** Limited (2.8 out of 5)
- **Verdict:** Meprin-β characterization across brain, CSF, and model systems offers an incremental Alzheimer's signal, but uncontrolled age confounding limits the central association.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs13195-026-02092-7

## Key claims

1. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen.
   - Support: Tentative
   - Type: Primary finding
   - Basis: age-imbalanced groups, indirect band assignment, uncorrected comparisons, and inconsistent dispersion reporting limit the late-Braak association
   - Location: Abstract; Results, Fig. 3B
2. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats.
   - Support: Tentative
   - Type: Secondary
   - Basis: small exploratory comparisons and incompatible SEM–p-value reporting materially limit confidence in the CSF result
   - Location: Abstract; Results, Figs. 5–6
3. The meprin-β species are increased in human neuronal cultures treated with Aβ42.
   - Support: Tentative
   - Type: Secondary
   - Basis: one donor line, supraphysiological treatment, and unreported independent differentiation counts constrain the observed response
   - Location: Abstract; Results, Fig. 4D
4. Our data support a role of meprin-β in Alzheimer's pathology.
   - Support: Tentative
   - Type: Secondary
   - Basis: cross-sectional associations and one acute cell treatment do not identify a pathological role
   - Location: Abstract; Discussion, Summary
5. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls.
   - Support: Supported
   - Type: Secondary
   - Basis: adjacent frontal-cortex tissue showed stage-specific transcript differences, though the exploratory comparisons were not multiplicity-adjusted
   - Location: Abstract; Results, Fig. 3C

## Strengths

- **Knockout-supported antibody specificity checks** Brain and CSF from Mep1b-null mice were used alongside N-terminal and C-terminal antibodies to assess which immunoreactive bands were attributable to meprin-β.
  - Dimension: methodological rigour
  - Location: Results, Figs. 1A and 2A
- **Multiple systems address one question** The study examines human brain, human CSF, iPSC-derived neurons, TgF344-AD rat CSF, and knockout mouse material, providing convergent descriptive observations across matrices and species.
  - Dimension: contribution
  - Location: Methods; Results, Figs. 1–6
- **Key assay limitations are acknowledged** The Discussion states that molecular mass does not directly prove maturation, brain and CSF samples were unpaired, activity was not measured, and independent replication is needed.
  - Dimension: positioning
  - Location: Discussion, limitations paragraphs

## Limitations

- **Age confounding affects brain comparison** Controls averaged 55 years, whereas Braak V–VI cases averaged 75 years, and no matched or between-group age-adjusted analysis was reported. Within-group correlations do not isolate disease status from this imbalance.
  - Dimension: methodological rigour
  - Location: Methods, Human Brain and CSF Samples; Results, Fig. 3B
- **Quantitative reporting does not cohere** Values are declared to be means ± SEM, yet examples such as CSF 171 ± 108% with p=0.041 appear incompatible with that convention. Effect magnitudes are also described inconsistently as relative levels or increases.
  - Dimension: reporting
  - Location: Methods, Statistical Analysis; Results, Figs. 3B–6B
- **Species assignment remains indirect** The mature-versus-zymogen interpretation rests principally on an approximately 10 kDa mobility difference without a pro-domain or processed-N-terminus antibody, and enzymatic activity was not measured.
  - Dimension: methodological rigour
  - Location: Discussion, meprin-β species interpretation and limitations paragraphs

## Reliability checks

Concerns (4 of 4 checks).

- **Results check:** Concern
  - Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats: "When we compared the levels of meprin-β in control and AD cases, we obtained elevated levels of the mature meprin-β in the CSF of patients with AD (171 ± 108%; p = 0.041), while the level of the zymogen remained unaltered (Fig. 5B)." (Results, Meprin-β is increased in the CSF of AD patients, Fig. 5B) vs "The results are presented as the means ± standard error of the mean (SEM), and all the analyses were performed using GraphPad Prism (version 7; GraphPad Software, Inc)." (Methods, Statistical analysis). With 15 subjects per group, control mean 100% under the stated normalization, and AD SEM 108%, the stated Student’s t-test gives |t| = 71/√(108² + SEM_control²) ≤ 0.6574 with 28 degrees of freedom, so its two-sided p-value is at least approximately 0.516 rather than 0.041. → Loses significance
  - The meprin-β species are increased in human neuronal cultures treated with Aβ42: "We demonstrated that Aβ42 can trigger an increase in the levels of the meprin-β attributed to the mature species (69 ± 15%; p = 0.001), as well for the zymogen species (50 ± 20%; p = 0.032), compared with controls (Fig. 4C)." (Results, iPSC-derived neurons treated with Aβ42) vs "D Quantification of the levels of meprin-β immunoreactive bands attributed to mature and zymogen levels was normalized to loading control α-tubulin and expressed as percentages with respect to controls." (Fig. 4D caption). The reported 69% and 50% denote increases in the Results wording but levels below the 100% control baseline under the caption’s convention, and the supplied text does not establish which convention describes the measurements. → Effect on result unclear
  - Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats: "CSF meprin-β levels were higher in TgF344-AD animals than in wild-types (63 ± 25%; p = 0.026, Fig. 6B)." (Results, TgF344-AD rat CSF) vs "B Data are expressed as percentages with respect to wild-type control rats." (Fig. 6B caption). A level of 63% of wild-type controls would be 37% lower, whereas a 63% increase would be a level of 163%, and the Results and caption do not establish which quantity was measured. → Effect on result unclear
- **Reporting and transparency:** Noted. The immunoprecipitation antibody identifier conflicts between Methods and Results, and the CSF characterization caption identifies brain homogenate as its material; neither issue establishes a corrected quantitative result.
  - Ethics approval: declared · Preregistration: not stated · Data availability: not stated
- **Reference integrity:** Clean
  - 48 references in manuscript
  - 48 of 48 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
